secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001641172-25-017285
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera acquires U.S. rights to Ameluz/RhodoLED from Biofrontera AG; raises $11M via Series C preferred
--------------------------------------------------------------------------------

- Acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG; will pay royalty of 12% or 15% based on $65M revenue threshold.
- Biofrontera AG receives 3,109 Series D Convertible Preferred shares (10% post-money equity stake) as part of consideration.
- Private placement of up to 11,000 Series C Preferred shares at $1,000 each for gross proceeds of up to $11.0M to fund the deal.
- Initial closing of $8.5M expected July 1, 2025; subsequent closing of $2.5M expected by September 30, 2025.
- Conversion and voting rights of both preferred series are subject to stockholder approval under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225017285/0001641172-25-017285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225017285/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer